PT  - JOURNAL ARTICLE
AU  - de Almeida, Dalziza Victalina
AU  - Cezar, Priscila Alves
AU  - Fernandes, Thais Freitas Barreto
AU  - Schwarz, Marcos Gustavo Araujo
AU  - Mendonça-Lima, Leila
AU  - Giacoia-Gripp, Carmem Beatriz Wagner
AU  - Côrtes, Fernanda Heloise
AU  - Lindenmeyer Guimarães, Monick
AU  - Pilotto, Jose Henrique
AU  - de Sá, Nathalia Beatriz Ramos
AU  - Cazote, Andressa da Silva
AU  - Gomes, Larissa Rodrigues
AU  - Quintana, Marcel de Souza Borges
AU  - Ribeiro-Alves, Marcelo
AU  - Coelho, Lara
AU  - Geraldo, Kim Mattos
AU  - Ribeiro, Maria Pia Diniz
AU  - Cardoso, Sandra Wagner
AU  - Grinsztejn, Beatriz Gilda Jegerhom
AU  - Santos, Valdiléa Gonçalves Veloso dos
AU  - Morgado, Mariza Gonçalves
TI  - The impact of early anti-SARS-CoV-2 antibody production on the length of hospitalization stay among COVID-19 patients
AID  - 10.1101/2023.03.02.23286693
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.03.02.23286693
4099  - http://medrxiv.org/content/early/2023/03/02/2023.03.02.23286693.short
4100  - http://medrxiv.org/content/early/2023/03/02/2023.03.02.23286693.full
AB  - COVID-19 has challenged the scientific community in the search for biological markers and information that can contribute to the early management of the severe disease. Given the global scale of COVID-19, including reports of reinfection even in the presence of effective vaccines, we have not yet been able to eradicate the disease. This factor implies the emergence of new waves and an increasing number of hospitalizations. This study aimed to characterize the neutralizing antibody (Nab) geometric mean titers (GMTs) in hospitalized patients with COVID-19 and to evaluate the association with length of stay, comorbidities, and patient outcome. Among the 103 participants, 84 (81.5%) had some previous condition associated with worsening health, and 31 (30%) died. We found that neutralization potency varied greatly across individuals and was significantly higher in patients discharged before 14 days than in patients who stayed longer in the hospital. During the study period, 15 people living with HIV (PLWH) were hospitalized, and no significant difference in clinical characteristics or anti-SARS-CoV-2 Nabs was observed. However, PLWH with severe COVID-19 were younger (41.7, IQR=17.5) than other hospitalized COVID-19 patients (59.3, IQR=22, P <0.01). A high anti-HIV-1 antibody GMT of 583.9 (95% CI: 344-990) was detected, demonstrating maintenance of anti-HIV-1 Nab production among PLWH coinfected with SARS-CoV-2. Therefore, these results indicate that neutralizing antibodies are not the only immunological response capable of controlling disease progression. Nevertheless, these data highlight the importance of more Nab screening studies to predict shorter hospital stays.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by FAPERJ/BR (Grant numbers SEI-260003/013002/2021) and INOVA FIOCRUZ/BR (Grant numbers SEI-25380.001587/2020-20).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the National Institute of Infectology Evandro Chagas (INI)/ Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil, under the approval number CAAE 32449420.4.1001.5262. All participants or their legal representatives signed an informed consent form prior to enrollment in the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript